Blueprint Medicines (NASDAQ:BPMC) PT Raised to $46.00

Blueprint Medicines (NASDAQ:BPMC – Get Rating) had its price target boosted by Barclays from $44.00 to $46.00 in a research report sent to investors on Tuesday, The Fly reports.

BPMC has been the subject of a number of other reports. Needham & Company LLC reissued a buy rating and issued a $57.00 target price on shares of Blueprint Medicines in a research note on Wednesday, April 19th. StockNews.com started coverage on Blueprint Medicines in a research note on Thursday, May 18th. They issued a hold rating for the company. Stifel Nicolaus upped their price objective on Blueprint Medicines from $80.00 to $84.00 in a research report on Tuesday, March 21st. HC Wainwright upped their price objective on Blueprint Medicines from $70.00 to $75.00 in a research report on Friday, May 5th. Finally, JMP Securities reaffirmed a market outperform rating and set a $114.00 price objective on shares of Blueprint Medicines in a research report on Thursday, March 30th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $72.84.

Blueprint Medicines Trading Up 4.0 %

BPMC stock opened at $58.50 on Tuesday. The company has a quick ratio of 5.11, a current ratio of 5.21 and a debt-to-equity ratio of 0.29. Blueprint Medicines has a twelve month low of $37.82 and a twelve month high of $79.40. The business has a fifty day moving average of $48.63 and a 200-day moving average of $46.29. The company has a market cap of $3.54 billion, a P/E ratio of -6.02 and a beta of 0.72.

Blueprint Medicines (NASDAQ:BPMC – Get Rating) last posted its earnings results on Thursday, May 4th. The biotechnology company reported ($2.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.51. Blueprint Medicines had a negative return on equity of 100.31% and a negative net margin of 284.02%. The firm had revenue of $63.29 million during the quarter, compared to analysts’ expectations of $41.85 million. During the same period in the previous year, the firm earned ($1.79) earnings per share. The company’s revenue was up .9% on a year-over-year basis. As a group, equities research analysts expect that Blueprint Medicines will post -9.59 EPS for the current year.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 9,793 shares of the company’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $45.67, for a total value of $447,246.31. Following the sale, the director now owns 173,450 shares in the company, valued at $7,921,461.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Jeffrey W. Albers sold 9,793 shares of the stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $45.67, for a total transaction of $447,246.31. Following the transaction, the director now owns 173,450 shares in the company, valued at $7,921,461.50. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Christina Rossi sold 3,059 shares of the stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $45.67, for a total value of $139,704.53. Following the transaction, the chief operating officer now owns 55,376 shares in the company, valued at approximately $2,529,021.92. The disclosure for this sale can be found here. Insiders have sold 27,696 shares of company stock worth $1,265,091 over the last 90 days. Company insiders own 3.42% of the company’s stock.

Institutional Investors Weigh In On Blueprint Medicines

Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its holdings in shares of Blueprint Medicines by 0.3% in the 1st quarter. Rhumbline Advisers now owns 81,233 shares of the biotechnology company’s stock valued at $3,655,000 after purchasing an additional 226 shares in the last quarter. Corton Capital Inc. lifted its stake in shares of Blueprint Medicines by 5.4% in the 1st quarter. Corton Capital Inc. now owns 4,898 shares of the biotechnology company’s stock valued at $220,000 after acquiring an additional 252 shares during the last quarter. E Fund Management Co. Ltd. lifted its stake in shares of Blueprint Medicines by 3.0% in the 1st quarter. E Fund Management Co. Ltd. now owns 9,195 shares of the biotechnology company’s stock valued at $414,000 after acquiring an additional 267 shares during the last quarter. Strs Ohio lifted its stake in shares of Blueprint Medicines by 15.8% in the 1st quarter. Strs Ohio now owns 2,200 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 300 shares during the last quarter. Finally, Van ECK Associates Corp lifted its stake in shares of Blueprint Medicines by 51.2% in the 4th quarter. Van ECK Associates Corp now owns 986 shares of the biotechnology company’s stock valued at $43,000 after acquiring an additional 334 shares during the last quarter.

Blueprint Medicines Company Profile

(Get Rating)

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.